Novartis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.

CEO

Vasant Narasimhan

CEOVasant Narasimhan

Employees

76,057

Employees76,057

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1996

Founded1996

Employees

76,057

Employees76,057

NVS Key Statistics

Market cap

211.79B

Market cap211.79B

Price-Earnings ratio

13.14

Price-Earnings ratio13.14

Dividend yield

3.28%

Dividend yield3.28%

Average volume

2.12M

Average volume2.12M

High today

$97.47

High today$97.47

Low today

$96.85

Low today$96.85

Open price

$97.26

Open price$97.26

Volume

1.30M

Volume1.30M

52 Week high

$108.78

52 Week high$108.78

52 Week low

$89.00

52 Week low$89.00

NVS News

Seeking Alpha 2h

Radiopharma stocks higher as sector welcomes the latest M&A deal

Shares of radiopharma companies spiked Thursday as investors welcomed the latest M&A deal to hit the sector, this time between Swiss pharma giant Novartis (NYSE...

Seeking Alpha 9h

Novartis to buy Mariana Oncology for $1B upfront

Novartis (NYSE:NVS) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments. The tr...

Yahoo Finance 1d

Novartis Is Tracking Well Above the Industry - Yahoo Finance

Novartis AG (NYSE:NVS) is one of the largest pharmaceutical companies in the world, many of whose drugs are "gold standards" in the treatment of cancer, heart f...

Analyst ratings

60%

of 25 ratings

Buy

32%

Hold

60%

Sell

More NVS News

Benzinga 3d

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

Loading... Loading... MorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. Myelo...

Seeking Alpha 4d

New safety risk for MorphoSys drug could complicate Novartis deal - STAT

A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale t...